In this review:
This review is a summary of a recent presentation by Dr James Demarest, Director of Microbiology Strategy at ViiV Healthcare. Dr Demarest discussed the scientific and clinical evidence for the high barrier to resistance of dolutegravir-based regimens in the treatment of HIV-1 infection. Dr Demarest’s talk was presented to healthcare professionals in Auckland via video by Dr Fraser Drummond, Medical Director Australasia ViiV Healthcare.
Download PDF